Wegovy (semaglutide)

Wegovy (semaglutide) is a prescription medicine indicated for chronic weight management in overweight and obese adults, as well as obese pediatric patients aged 12 years and up .

Wegovy (semaglutide)  is approved in the USA, EU, UK, Japan, and Canada

What is Wegovy (semaglutide) for?

Wegovy (semaglutide) is a medicine prescribed for chronic weight management. It’s intended for use in:

• Adult patients with BMI >30 kg/m2 (obese);
• Adult patients with BMI > 27 kg/m2 (overweight) and at least one weight-related comorbid condition, such as hypertension, type 2 diabetes, or dyslipidemia;
• Pediatric patients (12+) with BMI at the 95th percentile or greater for age and sex (obese).

Wegovy (semaglutide) is available as an injection, in pre-filled single-dose pens that deliver doses of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg.

How does Wegovy (semaglutide) work?

Wegovy’s active substance, semaglutide, is a GLP-1 receptor antagonist. It mimics the activity of GLP-1, a natural hormone in the body. Semaglutide appears to regulate appetite by increasing feelings of fullness. It reduces hunger and cravings, and, consequently, food intake.

Where has Wegovy (semaglutide) been approved?

Wegovy (semaglutide) is approved in the USA, EU, UK, Japan, and Canada